206 related articles for article (PubMed ID: 30375088)
1. Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.
Canese R; Palombelli G; Chirico M; Sestili P; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E
NMR Biomed; 2019 Oct; 32(10):e4016. PubMed ID: 30375088
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
3. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy.
Pisanu ME; Ricci A; Paris L; Surrentino E; Liliac L; Bagnoli M; Canevari S; Mezzanzanica D; Podo F; Iorio E; Canese R
Br J Cancer; 2014 Feb; 110(3):625-35. PubMed ID: 24335926
[TBL] [Abstract][Full Text] [Related]
4. Impact of Cold Ischemia on the Stability of
Ricci A; Dugo M; Pisanu ME; De Cecco L; Raspagliesi F; Valeri B; Veneroni S; Chirico M; Palombelli G; Daidone MG; Podo F; Canese R; Mezzanzanica D; Bagnoli M; Iorio E
J Proteome Res; 2024 Jan; 23(1):483-493. PubMed ID: 38109371
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and
Paris L; Podo F; Spadaro F; Abalsamo L; Pisanu ME; Ricci A; Cecchetti S; Altabella L; Buoncervello M; Lozneanu L; Bagnoli M; Ramoni C; Canevari S; Mezzanzanica D; Iorio E; Canese R
Oncotarget; 2017 Aug; 8(33):55022-55038. PubMed ID: 28903399
[TBL] [Abstract][Full Text] [Related]
6. In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy.
Lu J; Li Y; Li YA; Wang L; Zeng AR; Ma XL; Qiang JW
J Transl Med; 2022 Feb; 20(1):92. PubMed ID: 35168606
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI.
Yoon H; Yoon D; Yun M; Choi JS; Park VY; Kim EK; Jeong J; Koo JS; Yoon JH; Moon HJ; Kim S; Kim MJ
PLoS One; 2016; 11(7):e0159949. PubMed ID: 27459480
[TBL] [Abstract][Full Text] [Related]
8. In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.
Canese R; Mezzanzanica D; Bagnoli M; Indraccolo S; Canevari S; Podo F; Iorio E
Front Oncol; 2016; 6():164. PubMed ID: 27446810
[TBL] [Abstract][Full Text] [Related]
9. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Zeng Z; Lin C; Zhang MC; Kossinna P; Wang P; Cao D; Wang J; Xu M; Wang X; Li Q; Xu X; Yang H; Zhu S; Liu GR; Xie K; Yang J; Luo Y; Wang Y; Zhang XH; Lin J; Chen H; Liu SL; Liu H
Phytother Res; 2023 Oct; 37(10):4722-4739. PubMed ID: 37443453
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Mignion L; Danhier P; Magat J; Porporato PE; Masquelier J; Gregoire V; Muccioli GG; Sonveaux P; Gallez B; Jordan BF
Int J Cancer; 2016 Apr; 138(8):2043-9. PubMed ID: 26595604
[TBL] [Abstract][Full Text] [Related]
11. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
12. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
13. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.
Morse DL; Carroll D; Day S; Gray H; Sadarangani P; Murthi S; Job C; Baggett B; Raghunand N; Gillies RJ
NMR Biomed; 2009 Jan; 22(1):114-27. PubMed ID: 19016452
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
16. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
17. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
[TBL] [Abstract][Full Text] [Related]
18. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.
Hensley HH; Roder NA; O'Brien SW; Bickel LE; Xiao F; Litwin S; Connolly DC
Neoplasia; 2012 Jun; 14(6):451-62. PubMed ID: 22787427
[TBL] [Abstract][Full Text] [Related]
19. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
